Show simple item record

dc.contributor.authorPsallidas, Ioannis
dc.contributor.authorKalomenidis, Ioannis
dc.contributor.authorPorcel Pérez, José Manuel
dc.contributor.authorRobinson, Bruce W.
dc.contributor.authorStathopoulos, Georgios T.
dc.description.abstractMalignant pleural effusion (MPE) is a common but serious condition that is related with poor quality of life, morbidity and mortality. Its incidence and associated healthcare costs are rising and its management remains palliative, with median survival ranging from 3 to 12 months. During the last decade there has been significant progress in unravelling the pathophysiology of MPE, as well as its diagnostics, imaging, and management. Nowadays, formerly bed-ridden patients are genotyped, phenotyped, and treated on an ambulatory basis. This article attempts to provide a comprehensive overview of current advances in MPE from bench to bedside. In addition, it highlights unanswered questions in current clinical practice and suggests future directions for basic and clinical research in the field.ca_ES
dc.publisherEuropean Respiratory Societyca_ES
dc.relation.isformatofReproducció del document publicat a
dc.relation.ispartofEuropean Respiratory Review, 2016, vol. 25, núm. 140, p. 189-198ca_ES
dc.rightscc-by-nc (c) ERS, 2016ca_ES
dc.titleMalignant pleural effusion: from bench to bedsideca_ES

Files in this item


This item appears in the following Collection(s)

Show simple item record

cc-by-nc (c) ERS, 2016
Except where otherwise noted, this item's license is described as cc-by-nc (c) ERS, 2016